Edition:
United Kingdom

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

6.24USD
23 Jan 2018
Change (% chg)

$-0.24 (-3.70%)
Prev Close
$6.48
Open
$6.42
Day's High
$6.49
Day's Low
$6.11
Volume
210,521
Avg. Vol
94,645
52-wk High
$11.79
52-wk Low
$3.30

Chart for

About

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase... (more)

Overall

Beta: --
Market Cap(Mil.): $181.90
Shares Outstanding(Mil.): 29.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.27 16.62
EPS (TTM): -- -- --
ROI: -- 13.90 10.61
ROE: -- 16.71 14.21

BRIEF-Ocular Therapeutix Announces Kevin Hanley As Senior Vice President Technical Operations

* OCULAR THERAPEUTIX ANNOUNCES KEVIN HANLEY AS SENIOR VICE PRESIDENT, TECHNICAL OPERATIONS AND NAYMISHA PATEL AS VICE PRESIDENT OF QUALITY Source text for Eikon: Further company coverage:

08 Jan 2018

Ocular Therapeutix gets subpoena from SEC over eye pain drug

Ocular Therapeutix Inc said on Friday the U.S. Securities and Exchange Commission (SEC) had issued a subpoena seeking information about the company's eye-pain drug Dextenza.

22 Dec 2017

BRIEF-Ocular Therapeutix Provides Legal Update

* OCULAR THERAPEUTIX INC - ON DEC. 21, CO WAS SERVED WITH A NEW DERIVATIVE COMPLAINT

22 Dec 2017

Ocular Therapeutix gets subpoena from SEC over eye pain drug

Dec 22 Ocular Therapeutix Inc said on Friday the U.S. Securities and Exchange Commission (SEC) had issued a subpoena seeking information about the company's eye-pain drug Dextenza.

22 Dec 2017

BRIEF-Ocular Therapeutix posts Q3 loss per share $0.54

* Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update

07 Nov 2017

BRIEF-Ocular Therapeutix appoints Donald Notman as chief financial officer

* Ocular Therapeutix appoints Donald Notman as chief financial officer

25 Sep 2017

BRIEF-Ocular Therapeutix Q2 loss per share $0.64

* Ocular therapeutix™ reports second quarter 2017 financial results and provides corporate update

08 Aug 2017

BRIEF-Ocular hires Daniel Bollag for pharmacovigilance and quality

* Ocular Therapeutix appoints Daniel Bollag, PH.D., as senior vice president, regulatory affairs, pharmacovigilance and quality Source text for Eikon: Further company coverage:

03 Aug 2017

BRIEF-Ocular Therapeutix to eliminate 26 positions across organization

* Ocular Therapeutix says on july 31, board of directors approved a strategic restructuring to eliminate a portion of company's workforce - sec filing

01 Aug 2017

Earnings vs. Estimates